Prescribing patterns of combined hormonal products containing cyproterone acetate, levonorgestrel and drospirenone in the UK

Prothrombotic changes in users of combined oral contraceptives containing drospirenone and cyproterone acetate.

Statement on combined hormonal contraceptives containing third- or fourth-generation progestogens or cyproterone acetate, and the associated risk of thromboembolism.

Cosignatories Jean-Jacques Amy, Rob Beerthuizen, Martin Birkhäuser, Teresa Bombas, Mitchell Creinin, Philip D Darney, Lisa Ferreira Vicente, Kristina Gemzell-Danielsson, Bruno Imthurn, Jeffrey T Jensen, Andrew M Kaunitz, Ali Kubba, Medard M Lech, Diana Mansour, Gabriele Merki, Thomas Rabe, Katarina Sedlecki, David Serfaty, Jacques Seydoux, Lee P Shulman, Regine Sitruk-Ware, Sven O Skouby, Anne ...

Comparison of the Effects of Combined Oral Contraceptives Containing Progestins with Low Androgenic and Anti-androgenic Activities on the Clinical, Androgenic, and Metabolic Manifestations of Polycystic Ovary Syndrome

Introduction: Combined oral contraceptives (COCs) are commonly considered as the first-line treatment for polycystic ovary syndrome (PCOS). This study aimed to compare the effects of COCs with respect to their progestin component on the clinical, hormonal, and metabolic outcomes of women with PCOS. Data were extracted by searching PubMed, Scopus, EMBASE, and Google Scholar, without any time lim...

Comment on 'Statement on combined hormonal contraceptives containing third- or fourth-generation progestogens or cyproterone acetate, and the associated risk of thromboembolism': author's response.

I would like to thank Drs Terplan and Zuckerman for their comments on the recently published position statement, which myself and the other cosignatory authors take very seriously. If I may summarise Drs Terplan and Zuckerman‘s argument. It starts with the assumption that there is now clear evidence proving that levonorgestel (LNG)and norethisterone acetate (NETA)-containing combined oral contr...

Comparative risks of venous thromboembolism among users of oral contraceptives containing drospirenone and levonorgestrel.

Commentary Background Two case-control studies, both with the involvement of the Boston Collaborative Drug Surveillance Program, have recently been published in the British Medical Journal (Jick et al. 1 and Parkin et al. 2) in which increased risks of venous throm-boembolism (VTE) among users of drospirenone (DRSP)-containing oral contraceptives (OCs) compared with lev-onorgestrel (LNG)-contai...